Innate Pharma S.A.
IPHYF
$1.45
-$0.31-17.61%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -42.32% | -15.60% | 4.74% | -0.12% | -5.94% |
| Total Other Revenue | 6.54% | 15.99% | 23.14% | -10.29% | -32.91% |
| Total Revenue | -34.36% | -10.85% | 7.27% | -1.91% | -11.73% |
| Cost of Revenue | -5.00% | 3.92% | 11.37% | 9.91% | 6.69% |
| Gross Profit | -298.45% | -1,017.05% | -21.56% | -96.02% | -192.23% |
| SG&A Expenses | -0.35% | -7.97% | -16.64% | -22.12% | -28.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.84% | 0.64% | 2.86% | -0.27% | -4.77% |
| Operating Income | -62.26% | -32.45% | 14.26% | -5.16% | -14.83% |
| Income Before Tax | 41.95% | 63.00% | 85.94% | 12.99% | -148.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.95% | 63.00% | 85.94% | 12.99% | -148.31% |
| Earnings from Discontinued Operations | -- | -- | -- | 95.93% | 95.60% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.01% | 63.06% | 85.98% | 14.42% | -136.19% |
| EBIT | -62.26% | -32.45% | 14.26% | -5.16% | -14.83% |
| EBITDA | -101.61% | -52.21% | 28.03% | 1.50% | -11.38% |
| EPS Basic | 42.94% | 63.64% | 86.18% | 14.34% | -138.17% |
| Normalized Basic EPS | -49.87% | -8.31% | 51.23% | 12.59% | -13.76% |
| EPS Diluted | 42.87% | 63.48% | 86.02% | 13.94% | -140.02% |
| Normalized Diluted EPS | -49.24% | -7.82% | 51.32% | 13.18% | -12.96% |
| Average Basic Shares Outstanding | 1.01% | 1.02% | 1.02% | 0.51% | 0.00% |
| Average Diluted Shares Outstanding | -1.77% | 0.99% | 2.49% | 1.98% | 1.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |